๐ฐ Instil Bio News
Page 2 - Instil Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Instil Bio. Real-time updates on events, politics, business and more.
August 14, 2023
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023Initial data from ITIL-306-202 clin...
July 31, 2023
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the appointment of James Stutz, a business and finance executive with over 20 years of experience in the biopharma industry, as chief financial officer (CFO) and chief business officer (CBO). “We are delighted to welcome James to the Neurona team and look forward to the va...
July 21, 2023
Turnstone Biologics isnโt the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.
June 6, 2023
CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.In contrast to prior findings in melanoma, no biomarkers appeared prognostic for RFS among patients who received placebo.
May 15, 2023
The Supreme Court's consideration of the standards for satisfying the enablement provisions of 35 U.S.C. § 112(a) has been occasioned for the first time in over a century by the Court's...
April 26, 2023
Senior editor Fay Lin interviews Geulah Livshits,senior research analyst at Chardan,. She asks him to assess the advances and challenges facing the cell therapy field.
April 20, 2023
Former Kite Pharma Executive Responsible for the Development and Commercial Launch of Two of the Most Successful Autologous CAR T Manufacturing Processes...
April 17, 2023
Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.
April 16, 2023
The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared to immunotherapy alone, a new clinical trial shows.